The European Medicines Agency (EMA) has given the green light to the first combination vaccine protecting against both COVID-19, and influenza. The vaccine is approved for utilize in individuals aged 50 years and older, the agency announced on February 27, 2026. This approval offers a streamlined approach to preventative care against two common respiratory illnesses.
Final approval now rests with the European Commission, a step considered a formality. Following the Commission’s approval, individual EU member states will decide whether to offer the vaccine to their populations.
Familiar Vaccine Technology
According to the EMA, the Moderna vaccine, known as mCombriax, functions similarly to other existing vaccines. It prepares the body to defend against potential viral infections by containing mRNA building blocks that target both the COVID-19 virus and three strains of influenza. The individual vaccines that comprise the combination have already been authorized for several years.
Both influenza and COVID-19 primarily affect the respiratory system, often presenting with similar symptoms such as fever, cough, runny nose, and chills. While most infections are mild, they can be dangerous for older adults and individuals with weakened immune systems. Previously, individuals could protect themselves with two separate annual vaccinations. A combination vaccine could potentially ease the burden on healthcare systems.
Proven Effectiveness
The EMA reports that studies involving over 8000 participants aged 50 and older demonstrated the vaccine’s effectiveness. Individuals vaccinated with the combination product showed a comparable level of protection to those who received two separate vaccines.
Potential side effects, according to the EMA, include pain at the injection site, fatigue, muscle and headache, nausea, or fever. These symptoms are typically mild and resolve within two to three days.
© dpa-infocom, dpa:260227-930-746314/1
